Pharmaceutical Continuous Manufacturing Market is expected to reach US$ 26,253.37 Mn in 2027

by Sameer Joshi or 27-Apr-2020
     Request For Sample

Report : Pharmaceutical Continuous Manufacturing Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Product (Integrated Systems, Semi-Continuous Systems, Controls); Application (End Product Manufacturing, API Manufacturing); End User (Full-Scale Manufacturing Companies, R&D Departments) and Geography

Advantages offered by pharmaceutical continuous manufacturing process to drive the growth of the market

According to the new market research study of “Pharmaceutical Continuous Manufacturing Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Product (Integrated Systems, Semi-Continuous Systems, Controls); Application (End Product Manufacturing, API Manufacturing); End User (Full-Scale Manufacturing Companies, R&D Departments) and Geography,” the market is expected to reach US$ 3,064.38 million by 2027 from US$ 1,459.53 million in 2019. The market is estimated to grow with a CAGR of 9.8% from 2020 to 2027. The report highlights trends prevailing in the global pharmaceutical continuous manufacturing market and the factors driving market along with those that act as hindrances.

Batch manufacturing have been the most common and traditionally used mode of manufacturing in the pharmaceutical industry for more than a century. However, with the rising demand for biologics and increasing trend of contract manufacturing, the flexible manufacturing alternatives such as continuous manufacturing processes are being embraced and gaining importance in the recent years. The FDA is passing quick approvals to companies transitioning from batch production to continuous manufacturing procedures. In 2016, Orkambi by Vertex Pharmaceuticals was the first manufacturer to go “batch-less” on their production lines. Furthermore, in April 2019, Janssen Pharmaceuticals, a division of Johnson & Johnson Services, Inc., switched to continuous manufacturing process for the development of active pharmaceutical ingredients (API) due to the advantages offered by this process in terms of streamlining the manufacturing procedure, ability to accelerate procedure and others. Continuous pharmaceutical manufacturing involves a drug taken from its base ingredients to final product with no need of halt or stop during the production. According to the Food and Drug Administration (FDA), the pharmaceutical manufacturing industry wastes up to US$ 50 billion every year on an average on inefficient processes. Continuous manufacturing serves to be a potential solution for the same problem. In addition, there are various other advantages offered by the continuous process that include more time-efficiency, reduced energy needs, and increased productivity, as well as reduction in overall wastage amounts. Furthermore, the risk of human error is also reduced in the continuous process due to a smaller number of people involved in the manufacturing process. Thus, the advantages offered by continuous manufacturing over batch manufacturing procedure are expected to drive the growth of the market during the coming years.

North America held the largest market for the pharmaceutical continuous manufacturing during the forecast period. The encouragement from government and pharmaceutical regulatory bodies, high investments by pharmaceutical companies into manufacturing and scaling-up production units, and increasing shortages of drugs are among the key factors driving the growth of this market. In addition, the acceptance of advanced technology from pharmaceutical companies is further expected to propel the growth of the market. In 2019, Asia Pacific was registered as the fastest-growing region in the global pharmaceutical continuous manufacturing market. The growth of the market in Asia Pacific is expected to grow at a faster pace owing to factors such as increasing number of pharmaceutical companies, rising Foreign Direct Investments in potential pharmaceutical markets such as India, China and South East Asian countries and increasing demand for novel technology to boost the production volumes of drugs and APIs.

Leading companies operating in the pharmaceutical continuous manufacturing market are GEA Group, Coperion GmbH, Gericke AG, Glatt GmbH, Hosokawa Micron Group, Munson Machinery Co. Inc., Powrex Corp, Thermo Fisher Scientific Inc., Freund-vector Corporation, Fette Compacting, Alexanderwerk, LEISTRITZ AG, KORSCH AG, ACG, Cadmach Machinery Co. Pvt. Ltd., and Hovione en Aesica. 

The report analyzes pharmaceutical continuous manufacturing market on the basis of following segments:

By Product

  •  Integrated Systems
  •  Semi-Continuous Systems
  •  Continuous Granulators
  •  Continuous Blenders
  •  Continuous Compressors

  •  Continuous Coaters
  •  Continuous Dryers
  •  Other Semi-Continuous Systems
  •  Controls

By Application

  •  End Product Manufacturing
  •  Solid Dosage Manufacturing
  •  Liquid Dosage Manufacturing
  •  API Manufacturing

By End User

  •  Full Scale Manufacturing Companies
  •  Pharmaceutical Companies
  •  Contract Manufacturing Organizations
  •  R&D Departments
  •  Contract Research Organizations
  •  Research Institutes

By Geography

  •  North America
    •  US
    •  Canada
    •  Mexico
  •  Europe
    •  France
    •  Germany
    •  UK
    •  Spain
    •  Italy
  •  Asia Pacific
    •  China
    •  India
    •  Japan
    •  Australia
    •  South Korea
  •  Middle East and Africa
    •  Saudi Arabia
    •  UAE
    •  South Africa
  •  South and Central America
    •  Brazil
    •  Argentina

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com